Senior insider sale
ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$50.58M
1.11M shares
What this filing means
ORBIMED ADVISORS LLC plans to sell 1.11M shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $50.58M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/23/2026ACC: 0000947871-26-000649
Director10% Owner
Since Mar 2020
1.11M
Shares to sell
$50.58M
Approx. market value
833.80K
Acquired (3 months)
2
Planned
1 completed
Securities Acquired — Last 3 Months1
Merger
N/A
2/23/2023
833.80KTotal acquired833.80K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/23/2023 | Merger N/A | 833.80K | — |
| Total | 833.80K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
272.32K
Market value
$12.26M
6/15/2026
Planned — Approximate Date
Nasdaq Stock MarketPlanned
Units to sell
787.02K
Market value
$36.17M
6/22/2026
Nasdaq Stock MarketPlanned
Units to sell
46.78K
Market value
$2.15M
6/22/2026
Total
Units
1.11M
Value
$50.58M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
6/15/2026 | 272.32K | $12.26M | — | Completed |
| Planned — Approximate Date | ||||
6/22/2026 | 787.02K | $36.17M | Nasdaq Stock Market | Planned |
6/22/2026 | 46.78K | $2.15M | Nasdaq Stock Market | Planned |
| Total | 1.11M | $50.58M | ||